Cited by 147Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentTryptophan and brain disorders

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Gomes, Felipe V., Llorente, Ricardo, Del Bel, Elaine A., Viveros, Maria-Paz, López-Gallardo, Meritxell, Guimarães, Francisco S.·2015·Schizophrenia Research

DOI 10.1016/j.schres.2015.01.015

Open this paper in CoChat — free account

Abstract

NMDA receptor hypofunction could be involved, in addition to the positive, also to the negative symptoms and cognitive deficits found in schizophrenia patients. An increasing number of data has linked schizophrenia with neuroinflammatory conditions and glial cells, such as microglia and astrocytes, have been related to the pathogenesis of schizophrenia. Cannabidiol (CBD), a major non-psychotomimetic constituent of Cannabis sativa with anti-inflammatory and neuroprotective properties induces antipsychotic-like effects. The present study evaluated if repeated treatment with CBD (30 and 60 mg/kg) would attenuate the behavioral and glial changes observed in an animal model of schizophrenia based on the NMDA receptor hypofunction (chronic administration of MK-801, an NMDA receptor antagonist, for 28 days). The behavioral alterations were evaluated in the social interaction and novel object recognition (NOR) tests. These tests have been widely used to study changes related to negative symptoms and cognitive deficits of schizophrenia, respectively. We also evaluated changes in NeuN (a neuronal marker), Iba-1 (a microglia marker) and GFAP (an astrocyte marker) expression in the medial prefrontal cortex (mPFC), dorsal striatum, nucleus accumbens core and shell, and dorsal hippocampus by immunohistochemistry. CBD effects were compared to those induced by the atypical antipsychotic clozapine. Repeated MK-801 administration impaired performance in the social interaction and NOR tests. It also increased the number of GFAP-positive astrocytes in the mPFC and the percentage of Iba-1-positive microglia cells with a reactive phenotype in the mPFC and dorsal hippocampus without changing the number of Iba-1-positive cells. No change in the number of NeuN-positive cells was observed. Both the behavioral disruptions and the changes in expression of glial markers induced by MK-801 treatment were attenuated by repeated treatment with CBD or clozapine. These data reinforces the proposal that CBD may induce antipsychotic-like effects. Although the possible mechanism of action of these effects is still unknown, it may involve CBD anti-inflammatory and neuroprotective properties. Furthermore, our data support the view that inhibition of microglial activation may improve schizophrenia symptoms.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2015.01.015

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The mouse brain in stereotaxic coordinates
Konsman, J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 16,796
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat
Hoover, W. B., & Vertes, R. P. (2007) · Brain Structure and Function · doi:10.1007/s00429-007-0150-4 · Cited by 1,365
The Neuropsychopharmacology of Phencyclidine From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
Jentsch, J. D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,329
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,230
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 993
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836

Show all 72 references

Sorted by citations

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 861
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup‐Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 320
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 268
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Boggs, D. L., Surti, T. S., Gupta, A., Gupta, S., Niciu, M. J., Pittman, B. P., Martin, A. M. S., Thurnauer, H., Davies, A., D’Souza, D. C., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4885-9 · Cited by 256
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
Seeman, P. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.195 · Cited by 189
Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 180
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A. S., Silva, R. H., & Abílio, V. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00482 · Cited by 167
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 154
Astrocytes as new targets to improve cognitive functions
Dallérac, G. M., & Rouach, N. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.003 · Cited by 155
Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
Mori, M., Meyer, E., Soares, L. M., Milani, H., Guimarães, F. S., & de Oliveira, R. M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.11.005 · Cited by 155
Sleep disturbances and severe stress as glial activators: key targets for treating central sensitization in chronic pain patients?
Nijs, J., Loggia, M. L., Polli, A., Moens, M., Huysmans, E., Goudman, L., Meeus, M., Vanderweeën, L., Ickmans, K., & Clauw, D. J. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1353603 · Cited by 156
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
Osborne, A. L., Solowij, N., Babic, I., Huang, X., & Weston–Green, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.40 · Cited by 147
Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice
Schiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135
Cannabidiol as a potential treatment for psychosis
Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 121
The cannabinoid system and microglia in health and disease
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 103
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Rohleder, C., Müller, J. K., Lange, B., & Leweke, F. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00422 · Cited by 94
Decrease in Adult Neurogenesis and Neuroinflammation Are Involved in Spatial Memory Impairment in the Streptozotocin-Induced Model of Sporadic Alzheimer’s Disease in Rats
Bassani, T. B., Bonato, J. M., Machado, M. M. F., Cóppola-Segovia, V., Moura, E. L. R., Zanata, S. M., de Oliveira, R. M. W., & Vital, M. A. B. F. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0645-9 · Cited by 91
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms
Silote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 98
Clinical uses of cannabis and cannabinoids in the United States
Levinsohn, E. A., & Hill, K. P. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116717 · Cited by 97
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
Štark, T., Kučerová, J., Iannotti, F. A., D’Addario, C., Marco, R. D., Pekařík, V., Dražanová, E., Piscitelli, F., Bari, M., Babinská, Z., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.035 · Cited by 90
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
da Silva, N. R., Gomes, F. V., Sonego, A. B., da Silva, N. R., & Guimarães, F. S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104749 · Cited by 88
Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent
Kasten, C. R., Zhang, Y., & Boehm, S. L. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00032 · Cited by 86
Alterations of Astrocytes in the Context of Schizophrenic Dementia
Tarasov, V. V., Svistunov, A. А., Chubarev, V. N., Sologova, S. S., Мухортова, П. А., Levushkin, D., Somasundaram, S. G., Kirkland, C. E., Бачурин, С. О., & Aliev, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01612 · Cited by 85
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease
Machado, M. M. F., Bassani, T. B., Cóppola-Segovia, V., Moura, E. L. R., Zanata, S. M., Andreatini, R., & Vital, M. A. B. F. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.11.005 · Cited by 84
HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia‐like animals
Večeřa, J., Bártová, E., Krejčí, J., Legartová, S., Komůrková, D., Kučerová, J., Štark, T., Dražanová, E., Kašpárek, T., Šulcová, A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25914 · Cited by 80
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms
Calpe-López, C., García-Pardo, M. P., & Aguilar, M. A. (2019) · Molecules · doi:10.3390/molecules24142583 · Cited by 79
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
Batalla, A., Janssen, H., Gangadin, S. S., & Bossong, M. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071058 · Cited by 79
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
Sonego, A. B., Prado, D. D. S., do Vale, G. T., Sepulveda-Diaz, J. E., Cunha, T. M., Tirapelli, C. R., Bel, E. A. D., Raisman‐Vozari, R., & Guimarães, F. S. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.09.014 · Cited by 79
Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System
Norris, C., Loureiro, M., Kramar, C. P., Zunder, J. S., Renard, J., Rushlow, W. J., & Laviolette, S. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.93 · Cited by 75
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats
Bonato, J. M., Bassani, T. B., Milani, H., Vital, M. A. B. F., & de Oliveira, R. M. W. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.009 · Cited by 72
The role of microglia in neuropsychiatric disorders and suicide
Brisch, R., Wojtylak, S., Saniotis, A., Steiner, J., Gos, T., Kumaratilake, J., Henneberg, M., & Wolf, R. J. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01334-z · Cited by 74
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid
Kozela, E., Juknat, A., & Vogel, Z. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081669 · Cited by 74
Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease
Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., & Cerri, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168920 · Cited by 69
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders
Lisboa, S. F. D. S., Gomes, F. V., Guimarães, F. S., & Campos, A. C. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00005 · Cited by 69
Microglia and BDNF at the crossroads of stressor related disorders: Towards a unique trophic phenotype
Prowse, N. A., & Hayley, S. P. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.09.018 · Cited by 72
Cannabidiol and brain function: current knowledge and future perspectives
Schouten, M., Dalle, S., Mantini, D., & Koppo, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328885 · Cited by 64
Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
Yousaf, M., Chang, D., Liu, Y., Liu, T., & Zhou, X. (2022) · Molecules · doi:10.3390/molecules27154961 · Cited by 64
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
Manseau, M. W., & GOFF, D. C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0382-6 · Cited by 60
Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia
Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Newell, K. A., Huang, X., & Weston–Green, K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109666 · Cited by 57
Adolescent social isolation affects schizophrenia-like behavior and astrocyte biomarkers in the PFC of adult rats
Sun, L., Min, L., Zhou, H., Li, M., Shao, F., & Wang, W. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.011 · Cited by 51
Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders
Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Huang, X., Newell, K. A., & Weston–Green, K. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.07.018 · Cited by 52
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi, J. F. C., Ferreira, F. R., Silva-Amaral, D., Lima, D. D. A., Hallak, J. E. C., Zuardi, A. W., Bel, E. A. D., Guimarães, F. S., Costa, K. C. M., Campos, A. C., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06196-4 · Cited by 53
Cannabidiol attenuates cognitive deficits and neuroinflammation induced by early alcohol exposure in a mice model
García-Baos, A., Puig-Reyné, X., García‐Algar, Ó., & Valverde, O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111813 · Cited by 46
Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats
Kozela, E., Krawczyk, M., Kos, T., Juknat, A., Vogel, Z., & Popik, P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01831-2 · Cited by 45
Social stress during adolescence activates long-term microglia inflammation insult in reward processing nuclei
Rodríguez‐Arias, M., Montagud‐Romero, S., Carrión, A. M. G., Perez, C. F., Pérez‐Villalba, A., Marco, E. M., López‐Gallardo, M., Viveros, M., & Miñarro, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206421 · Cited by 42
Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders
Scarante, F. F., Ribeiro, M. A., Almeida-Santos, A. F., Guimarães, F. S., & Campos, A. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618065 · Cited by 44
Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology
Hudson, R., Rushlow, W. J., & Laviolette, S. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4766-7 · Cited by 40
Anti-inflammatory agents for smoking cessation? Focus on cognitive deficits associated with nicotine withdrawal in male mice
Saravia, R., Ten-Blanco, M., Grande, M. T., Maldonado, R. J., & Berrendero, F. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.11.003 · Cited by 39
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
Davies, C., Wilson, R. P., Appiah‐Kusi, E., Blest‐Hopley, G., Brammer, M. J., Pérez, J., Murray, R. M., Allen, P., Bossong, M. G., McGuire, P. K., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0862-2 · Cited by 40
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Štark, T., Martino, S. D., Drago, F., Wotjak, C. T., & Micale, V. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105938 · Cited by 37
Effects of enriched environment on alterations in the prefrontal cortex GFAP- and S100B-immunopositive astrocytes and behavioral deficits in MK-801-treated rats
Rahati, M., Nozari, M., Eslami, H., Shabani, M., & Basiri, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.065 · Cited by 34
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies
Schoevers, J. M. H., Leweke, J. E., & Leweke, F. M. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000596 · Cited by 34
Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
Pereira, M. D. S., de Abreu, G. H. D., Rocca, J., Hamadat, S., Raisman‐Vozari, R., Michel, P. P., & Bel, E. A. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.617085 · Cited by 35
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Cortez, I. L., da Silva, N. R., Guimarães, F. S., & Gomes, F. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.587154 · Cited by 29
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Veselinović, T., & Neuner, I. (2022) · CNS Drugs · doi:10.1007/s40263-022-00935-z · Cited by 31
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Loss, C. M., Teodoro, L., Rodrigues, G. D., Moreira, L. R., Peres, F. F., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Abílio, V. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.635763 · Cited by 27
Cannabidiol Attenuates MK-801-Induced Cognitive Symptoms of Schizophrenia in the Passive Avoidance Test in Mice
Kruk-Słomka, M., & Biała, G. (2021) · Molecules · doi:10.3390/molecules26195977 · Cited by 27
Reactive Transformation and Increased BDNF Signaling by Hippocampal Astrocytes in Response to MK-801
Yu, W., Zhu, H., Wang, Y., Li, G., Wang, L., & Li, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145651 · Cited by 27
NMDA receptor antagonism by repetitive MK801 administration induces schizophrenia-like structural changes in the rat brain as revealed by voxel-based morphometry and diffusion tensor imaging
Wu, H., Wang, X., Gao, Y., Lin, F., Song, T., Zou, Y., Xu, L., & Lei, H. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.043 · Cited by 24
Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine
Wei, Y., Xiao, L., Fan, W., Zou, J., Yang, H., Liu, B., Ye, Y., Wen, D., & Liao, L. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02046-2 · Cited by 23
Cannabinoids and glial cells: possible mechanism to understand schizophrenia
de Almeida, V., & Martins‐de‐Souza, D. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0874-6 · Cited by 23
Molecular Plasticity of the Nucleus Accumbens Revisited—Astrocytic Waves Shall Rise
Kardos, J., Dobolyi, Á., Szabó, Z. M., Simon, Á., Lourmet, G. S., Palkovits, M., & Héja, L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1641-z · Cited by 22
Applications of Cannabinoids in Neuropathic Pain: An Updated Review
Arthur, P., Kalvala, A. K., Surapaneni, S. K., & Singh, M. S. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022038592 · Cited by 21
The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 20
Cannabidiol as potential treatment in refractory pediatric epilepsy
Paolino, M. C., Ferretti, A., Papetti, L., Villa, M. P., & Parisi, P. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1121098 · Cited by 20
Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice
Ledesma, J. C., Manzanedo, C., & Aguilar, M. A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110390 · Cited by 21
Profiling MicroRNAs with Associated Spatial Dynamics in Acute Tissue Slices
Xie, K., Wang, Z., Lin, Q., Zhao, X., Wang, Y., Jin, Q., Xu, P., Huang, L., Zhang, W., Yang, Y., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c09676 · Cited by 18
New insight in the cross-talk between microglia and schizophrenia: From the perspective of neurodevelopment
Li, J., Wang, Y., Yuan, X., Kang, Y., & Song, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1126632 · Cited by 19
Sleep-wake cycle disturbances and NeuN-altered expression in adult rats after cannabidiol treatments during adolescence
Murillo‐Rodríguez, E., Millán‐Aldaco, D., Cicconcelli, D., Giorgetti, V., Arankowsky‐Sandoval, G., Alcaraz-Silva, J., Imperatori, C., Machado, S. E. D. C., Budde, H., & Torterolo, P. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05769-z · Cited by 20
Cannabidiol—A friend or a foe?
Tihăuan, B.-M., Onisei, T., Slootweg, W., Gună, D., Iliescu, C., & Chifiriuc, M. C. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107036 · Cited by 16
Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine
Brakatselos, C., Delis, F., Asprogerakas, M.-Z., Lekkas, P., Tseti, I. K., Tzimas, P. S., Petrakis, E. A., Halabalaki, M., Skaltsounis, A., & Antoniou, K. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.09.029 · Cited by 16
Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects
Hu, Z., Qin, Z., Xie, J., Qu, Y., & Yin, L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116271 · Cited by 15
Cannabidiol promotes neurogenesis in the dentate gyrus during an abstinence period in rats following chronic exposure to methamphetamine
Razavi, Y., Keyhanfar, F., Haghparast, A., Shabani, R., & Mehdizadeh, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00774-9 · Cited by 15
Do Astrocytes Respond To Dopamine ?
Jennings, A., & Rusakov, D. A. (2016) · Russian Agency for Digital Standardization · doi:10.20388/omp2016.001.0017 · Cited by 14
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Bartoli, F., Riboldi, I., Bachi, B., Calabrese, A., Moretti, F., Crocamo, C., & Carrà, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061303 · Cited by 16
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice
Sonego, A. B., Prado, D. D. S., & Guimarães, F. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110367 · Cited by 15
Impact of smoking cannabidiol (CBD)-rich marijuana on driving ability
Gelmi, T. J., Weinmann, W., & Pfäffli, M. (2021) · Forensic Sciences Research · doi:10.1080/20961790.2021.1946924 · Cited by 13
From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia
Hoffman, K. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.682611 · Cited by 13
Cannabidiol improves maternal obesity-induced behavioral, neuroinflammatory and neurochemical dysfunctions in the juvenile offspring
Rodrigues, F. D. S., Jantsch, J., Fraga, G. D. F., Milczarski, V. L. D. C., Dias, V. S., Scheid, C., Merib, J. D. O., Giovernardi, M., & Guedes, R. P. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.010 · Cited by 13
Phytocannabinoids in neuromodulation: From omics to epigenetics
Banerjee, S., Saha, D., Sharma, R., Jaidee, W., Puttarak, P., Chaiyakunapruk, N., & Chaoroensup, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118201 · Cited by 13
The Antioxidant N-Acetyl-L-Cysteine Restores the Behavioral Deficits in a Neurodevelopmental Model of Schizophrenia Through a Mechanism That Involves Nitric Oxide
Lopes-Rocha, A. C., Bezerra, T. O., Zanotto, R., Nascimento, I. L., Rodrigues, A., & Salum, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924955 · Cited by 11
Protective effects of cannabidiol on cuprizone-induced demyelination in C57BL/6 mice
Sajjadian, M., Kashani, I. R., Pasbakhsh, P., Hassani, M., Omidi, A., Takzare, N., Clarner, T., Beyer, C., & Zendedel, A. (2017) · Journal of Contemporary Medical Sciences · doi:10.22317/jcms.09201707 · Cited by 11
Emerging role of microglia and astrocyte in the affective-motivational response induced by a rat model of persistent orofacial pain
Nascimento, G. C., Lucas, G., & Leite‐Panissi, C. R. A. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.02.005 · Cited by 10
Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis
Hazani, R., Michal Lavidor, B., & Weller, A. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac093 · Cited by 8
Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies
Jankowska, A., Satała, G., Partyka, A., Wesołowska, A., Bojarski, A. J., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190710172002 · Cited by 10
The Endocannabinoid System in Prefrontal Synaptopathies
Scheyer, A. F., Martin, H. G. S., & Manzoni, O. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-57371-7_7 · Cited by 10
Therapeutic potential of CBD in Autism Spectrum Disorder
Pedrazzi, J. F. C., Hassib, L., Ferreira, F. R., Hallak, J. E. C., Del-Bel, E., & Crippa, J. A. S. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.05.002 · Cited by 12
Differential behavioral and glial responses induced by dopaminergic mechanisms in the iNOS knockout mice
Issy, A. C., Nascimento, G. C., de Abreu, G. H. D., Tristão, F. S. M., Bel, E. A. D., Duarte, T. T., & Bortolanza, M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.002 · Cited by 8
Cannabinoid Modulation of Object Recognition and Location Memory—A Preclinical Assessment
Chesworth, R., Watt, G., & Karl, T. (2018) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-812012-5.00031-8 · Cited by 8
The antipsychotic-like effects of clozapine in C57BL/6 mice exposed to cuprizone: Decreased glial activation
Chang, H., Wei, Y., Chen, Y., Du, L., Cong, H., Zhang, X., Geng, X., & Yin, L. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.026 · Cited by 8
Citicoline and Coenzyme Q10: Therapeutic Agents for Glial Activation Reduction in Ocular Hypertension
Matamoros, J. A., Rubio‐Casado, S., Fernández‐Albarral, J. A., Martínez‐López, M. A., Ramirez, A. I., Salobrar‐García, E., Marco, E. M., Paleo‐García, V., de Hoz, R., López‐Cuenca, I., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050694 · Cited by 7
Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia
Abdelfattah, A. M., Abuelezz, S. A., Hendawy, N., Negm, E. A., Nawishy, S., & Khalil, A. M. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2022.121366 · Cited by 7
Cannabidiol as an antipsychotic drug
Fabris, D., Lisboa, J. R., Guimarães, F. S., & Gomes, F. V. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.013 · Cited by 7
Neuronal and glial region dependent changes in female mice from a model of premature aging
Garrido, A., de la Serna, M., la Fuente, M. D., Marco, E. M., & López‐Gallardo, M. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111224 · Cited by 7
The Use of Cannabidiol in Treating Psychiatric Disorders: A Systematic Review
Pavel, A. N., Paun, R., & Matei, V. P. (2021) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2021.21743 · Cited by 6

Authors: Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S.
Affiliations: Universidade de São Paulo (BR)
Universidad Complutense de Madrid (ES)
ORCID: Gomes, Felipe V.
Llorente, Ricardo
Guimarães, Francisco S.
Venue: Schizophrenia Research
Publisher: Elsevier BV
Published: 2015-05
Volume: 164
Issue: 1-3
Pages: 155-163
ISSN: 0920-9964 (ISSN-L)
DOI: 10.1016/j.schres.2015.01.015
OpenAlex: W2028951205
Cited by: 147
References: 72
Citations by year: 2026: 4 · 2025: 13 · 2024: 15 · 2023: 8 · 2022: 13 · 2021: 24 · 2020: 11 · 2019: 14 · 2018: 15 · 2017: 14 · 2016: 12 · 2015: 4
FWCI: 10.86
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Schizophrenia Research (publishedVersion)
PubMed (publishedVersion)
Library Open Repository (Universidad Complutense Madrid) (submittedVersion)
Funders: FAPESP (012/17626-7)
CNPq (470311/2012-6)
Instituto de Salud Carlos III, Redes temáticas de Investigación Cooperativa en salud (RD2012/0028/0021)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: cannabidiol, schizophrenia
MeSH terms: Animals, Brain, Calcium-Binding Proteins, Cannabidiol, Clozapine, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Gene Expression Regulation, Glial Fibrillary Acidic Protein, Male, Mice, Inbred C57BL, Microfilament Proteins, Neuroglia, Phosphopyruvate Hydratase, Psychotic Disorders, Antipsychotic Agents, Dizocilpine Maleate, Excitatory Amino Acid Antagonists, Maze Learning, Recognition, Psychology, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks